CYCLOMEDICA EUROPE LIMITED

Cyclomedica Europe Limited is a globally recognised leader in nuclear medicine and molecular imaging, dedicated to advancing functional lung imaging for the benefit of patients with respiratory disease. The company’s flagship product, Technegas®, has been used in over 4.7 million procedures since its clinical approval in 1986 and is now expanding beyond the traditional diagnosis of pulmonary embolism to address chronic thromboembolic pulmonary hypertension, COPD, asthma, radiotherapy planning and even complications of COVID‑19. By combining the unique aerosol‑based technology of Technegas® with cutting‑edge imaging techniques and artificial‑intelligence analytics, Cyclomedica provides clinicians with a powerful tool to diagnose, assess, monitor and plan treatment for a wide range of lung conditions.

Cyclomedica operates from a network of international hubs, with its global headquarters situated in Australia and additional offices across the United States, Europe, Asia and Latin America. This extensive footprint enables the company to support healthcare providers worldwide, delivering innovative imaging solutions that improve clinical outcomes and illuminate the future of pulmonary care.